Stomach Cancer Treatment Market (By Treatment Type; By Disease Indication; By Route of Administration; By Drug Class; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Stomach Cancer Treatment Market 

5.1. COVID-19 Landscape: Stomach Cancer Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Stomach Cancer Treatment Market, By Treatment Type

8.1. Stomach Cancer Treatment Market, by Treatment Type, 2022-2030

8.1.1. Immunotherapy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Targeted Therapy

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Chemotherapy

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Radiation Therapy And Surgery (Qualitative Analysis Only)

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Stomach Cancer Treatment Market, By Disease Indication

9.1. Stomach Cancer Treatment Market, by Disease Indication, 2022-2030

9.1.1. Gastric Cancer/Gastroesophageal Junction Cancer

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Gastrointestinal Stromal Tumors

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Snacks

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Stomach Cancer Treatment Market, By Route of Administration 

10.1. Stomach Cancer Treatment Market, by Route of Administration, 2022-2030

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Injectable

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Stomach Cancer Treatment Market, By Drug Class

11.1. Stomach Cancer Treatment Market, by Drug Class, 2022-2030

11.1.1. PD-1/PD-L1 Inhibitors

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. HER2 Antagonists

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. VEGFR2 Antagonists

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Stomach Cancer Treatment Market, By Distribution Channel

12.1. Stomach Cancer Treatment Market, by Distribution Channel, 2022-2030

12.1.1. Hospital Pharmacies

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Specialty & Retail Pharmacies

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Others

12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Stomach Cancer Treatment Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.1.7. Market Revenue and Forecast, by Distribution Channel (2017-2030) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.1.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.1.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.8.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.1.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.4. Market Revenue and Forecast, by Drug Class (2017-2030) 

13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.7. Market Revenue and Forecast, by Drug Class (2017-2030) 

13.2.8. Market Revenue and Forecast, by Distribution Channel (2017-2030) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.10. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.11. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.2.12.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.2.14.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.15. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.3.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.3.11.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.4.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.4.11.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

13.5.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 14. Company Profiles

14.1. Novartis AG

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Pfizer, Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Mylan N.V.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. F. Hoffmann La Roche Ltd.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Eli Lilly And Company

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Merck & Co., Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Teva Pharmaceutical Industries Ltd.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Celltrion Healthcare Co., Ltd.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Samsung Bioepis

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Bristol Myers Squibb Company

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms